← feed

Is NCT02870231 results overdue?

Yes — results are overdue. Primary completion was 2017-09-03; the FDAAA-801 reporting deadline (2018-09-03) passed 2848 days ago and no results are posted on ClinicalTrials.gov.

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

NCT IDNCT02870231 ↗
SponsorNovo Nordisk A/S (INDUSTRY)
Public issuerNOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-09-03 (ACTUAL)
Reporting deadline2018-09-03 (completion + 365d)
Days overdue2848
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 0b57995bbbdee07b… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02870231. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →